Estimates Revisions Compass Therapeutics, Inc. OTC Markets
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
|
Delayed
OTC Markets
15:59:57 2021-11-03 EDT
|
5-day change | 1st Jan Change | ||
| 3.550 USD | -10.80% |
|
+32.67% | - |
| 09-23 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Compass Therapeutics, Inc.(CMPX)
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
- Stock Market
- Stocks
- CMPX Stock
- CMPX Stock
- Consensus Compass Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
